Natural killer cells in patients with severe chronic fatigue syndrome

Autoimmunity Highlights

Volumn 4, Issue 3, 2013, Pages 69-80

  Brenu, E W ^a,d   Hardcastle, S L ^a   Atkinson, G M ^a   van Driel, M L ^b   Kreijkamp Kaspers, S ^c   Ashton, K J ^c   Staines, D R ^a,b   Marshall Gradisnik, S M ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b QUEENSLAND HEALTH   (Australia)

^c BOND UNIVERSITY   (Australia)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

Chronic fatigue syndrome; Cytotoxicity; Granzymes; Natural killer cells; Perforin

Indexed keywords

BETA INTERFERON; CD56 ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GRANZYME A; GRANZYME B; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MICRORNA; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; RANTES; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

CHRONIC FATIGUE SYNDROME; CYTOTOXICITY; DISEASE SEVERITY; GENE EXPRESSION; HUMAN; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84888264788     PISSN: 20380305     EISSN: 20383274     Source Type: Journal    
DOI: 10.1007/s13317-013-0051-x     Document Type: Review

References (130)

1. Galy A, Travis M, Cen D, Chen B (1995) Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 3(4): 459-473.
2. Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Investig 118(11): 3537-3545. doi: 10. 1172/JCI36389.
3. Barnes PJ (2008) The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Investig 118(11): 3546-3556. doi: 10. 1172/JCI36130.
4. Codarri L, Fontana A, Becher B (2010) Cytokine networks in multiple sclerosis: lost in translation. Curr Opin Neurol 23(3): 205-211. doi: 10. 1097/WCO. 0b013e3283391feb.
5. Steinman L (2008) Nuanced roles of cytokines in three major human brain disorders. J Clin Investig 118(11): 3557-3563. doi: 10. 1172/JCI36532.
6. Miron N, Miron MM, Milea VG, Cristea V (2010) Proinflammatory cytokines: an insight into pancreatic oncogenesis. Roum Arch Microbiol Immunol 69(4): 183-189.
7. Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1): i104-i108. doi: 10. 1136/ard. 2010. 140145.
8. Skinnider BF, Mak TW (2002) The role of cytokines in classical Hodgkin lymphoma. Blood 99(12): 4283-4297. doi: 10. 1182/blood-2002-01-0099.
9. Oppenheim J, Fujiwara H (1996) The role of cytokines in cancer. Cytokine Growth Factor Rev 7(3): 279-288.
10. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97(10): 3146-3151.
11. Caligiuri MA (2008) Human natural killer cells. Blood 112(3): 461-469. doi: 10. 1182/blood-2007-09-077438.
12. Vilches C, Parham P (2002) KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 20: 217-251.
13. Diaz-Pena R, Blanco-Gelaz MA, Lopez-Larrea C (2009) KIR genes and their role in spondyloarthropathies. Adv Exp Med Biol 649: 286-299.
14. Isakov N (1997) Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. J Leukoc Biol 61(1): 6-16.
15. Brumbaugh KM, Binstadt BA, Billadeau DD, Schoon RA, Dick CJ, Ten RM, Leibson PJ (1997) Functional role for Syk tyrosine kinase in natural killer cell-mediated natural cytotoxicity. J Exp Med 186(12): 1965-1974.
16. Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, Wei S, Djeu JY (2000) Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 1(5): 419-425. doi: 10. 1038/80859.
17. Jiang K, Zhong B, Gilvary DL, Corliss BC, Vivier E, Hong-Geller E, Wei S, Djeu JY (2002) Syk regulation of phosphoinositide 3-kinase-dependent NK cell function. J Immunol 168(7): 3155-3164.
18. Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107(1): 159-166. doi: 10. 1182/blood-2005-04-1351.
19. Zompi S, Hamerman JA, Ogasawara K, Schweighoffer E, Tybulewicz VL, Di Santo JP, Lanier LL, Colucci F (2003) NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat Immunol 4(6): 565-572. doi: 10. 1038/ni930.
20. Raulet DH (2006) Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol 18(3): 145-150. doi: 10. 1016/j. smim. 2006. 03. 003.
21. Voskoboinik I, Smyth MJ, Trapani JA (2006) Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 6(12): 940-952. doi: 10. 1038/nri1983.
22. Cullen SP, Martin SJ (2008) Mechanisms of granule-dependent killing. Cell Death Differ 15(2): 251-262. doi: 10. 1038/sj. cdd. 4402244.
23. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62(20): 5813-5817.
24. Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T, Izawa S, Fujii H (2010) NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. Dis Esophagus 23(8): 675-681.
25. Stratov I, Chung A, Kent SJ (2008) Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 82(11): 5450-5459.
26. Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, Stratov I (2011) Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA 108(18): 7505-7510.
27. Triulzi C, Vertuani S, Curcio C, Antognoli A, Seibt J, Akusjarvi G, Wei WZ, Cavallo F, Kiessling R (2010) Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res 70(19): 7431-7441. doi: 10. 1158/0008-5472. CAN-10-0493.
28. Wallin RP, Screpanti V, Michaelsson J, Grandien A, Ljunggren HG (2003) Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur J Immunol 33(10): 2727-2735. doi: 10. 1002/eji. 200324070.
29. Ochi M, Ohdan H, Mitsuta H, Onoe T, Tokita D, Hara H, Ishiyama K, Zhou W, Tanaka Y, Asahara T (2004) Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 39(5): 1321-1331. doi: 10. 1002/hep. 20204.
30. Screpanti V, Wallin RP, Grandien A, Ljunggren HG (2005) Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 42(4): 495-499. doi: 10. 1016/j. molimm. 2004. 07. 033.
31. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J, Tajouri L, Peterson D, Ramos SB, Marshall-Gradisnik SM (2012) Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 10: 88. doi: 10. 1186/1479-5876-10-88.
32. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, Klimas NG, Marshall-Gradisnik SM (2011) Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 9: 81. doi: 10. 1186/1479-5876-9-81.
33. Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M, Broderick G, Klimas NG (2010) Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS ONE 5(5): e10817. doi: 10. 1371/journal. pone. 0010817.
34. Brenu EW, Staines DR, Baskurt OK, Ashton KJ, Ramos SB, Christy RM, Marshall-Gradisnik SM (2010) Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med 8: 1. doi: 10. 1186/1479-5876-8-1.
35. Mihaylova I, DeRuyter M, Rummens JL, Bosmans E, Maes M (2007) Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuro Endocrinol Lett 28(4): 477-483.
36. Siegel SD, Antoni MH, Fletcher MA, Maher K, Segota MC, Klimas N (2006) Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: preliminary evidence for a subgroup? J Psychosom Res 60(6): 559-566. doi: 10. 1016/j. jpsychores. 2006. 03. 001.
37. Maher KJ, Klimas NG, Fletcher MA (2005) Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol 142(3): 505-511. doi: 10. 1111/j. 1365-2249. 2005. 02935. x.
38. Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B (2012) Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun 26(1): 24-31. doi: 10. 1016/j. bbi. 2011. 06. 016.
39. Lieberman J, Fan Z (2003) Nuclear war: the granzyme A-bomb. Curr Opin Immunol 15(5): 553-559.
40. Ashton-Rickardt PG (2005) The granule pathway of programmed cell death. Crit Rev Immunol 25(3): 161-182. doi: 2a1e865d14be9dc2, 1831b39d0d3647ea [pii].
41. Bovenschen N, Quadir R, van den Berg AL, Brenkman AB, Vandenberghe I, Devreese B, Joore J, Kummer JA (2009) Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A. Journal Biol Chem 284(6): 3504-3512. doi: 10. 1074/jbc. M806716200.
42. Sutton VR, Wowk ME, Cancilla M, Trapani JA (2003) Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity 18(3): 319-329. doi: S1074761303000505 [pii].
43. Heibein JA, Goping IS, Barry M, Pinkoski MJ, Shore GC, Green DR, Bleackley RC (2000) Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med 192(10): 1391-1402.
44. Lieberman J (2003) The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 3(5): 361-370. doi: 10. 1038/nri1083.
45. Baran K, Dunstone M, Chia J, Ciccone A, Browne KA, Clarke CJ, Lukoyanova N, Saibil H, Whisstock JC, Voskoboinik I, Trapani JA (2009) The molecular basis for perforin oligomerization and transmembrane pore assembly. Immunity 30(5): 684-695. doi: 10. 1016/j. immuni. 2009. 03. 016.
46. Law RH, Lukoyanova N, Voskoboinik I, Caradoc-Davies TT, Baran K, Dunstone MA, D'Angelo ME, Orlova EV, Coulibaly F, Verschoor S, Browne KA, Ciccone A, Kuiper MJ, Bird PI, Trapani JA, Saibil HR, Whisstock JC (2010) The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature 468(7322): 447-451. doi: 10. 1038/nature09518.
47. Cleare AJ (2003) The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 24(2): 236-252.
48. Di Giorgio A, Hudson M, Jerjes W, Cleare AJ (2005) 24-hour pituitary and adrenal hormone profiles in chronic fatigue syndrome. Psychosom Med 67(3): 433-440. doi: 10. 1097/01. psy. 0000161206. 55324. 8a.
49. Fulle S, Belia S, Vecchiet J, Morabito C, Vecchiet L, Fano G (2003) Modification of the functional capacity of sarcoplasmic reticulum membranes in patients suffering from chronic fatigue syndrome. Neuromuscul Disord NMD 13(6): 479-484.
50. Goertzel BN, Pennachin C, de Souza Coelho L, Gurbaxani B, Maloney EM, Jones JF (2006) Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome. Pharmacogenomics 7(3): 475-483. doi: 10. 2217/14622416. 7. 3. 475.
51. Klimas NG, Koneru AO (2007) Chronic fatigue syndrome: inflammation, immune function, and neuroendocrine interactions. Curr Rheumatol Rep 9(6): 482-487.
52. Lange G, DeLuca J, Maldjian JA, Lee H, Tiersky LA, Natelson BH (1999) Brain MRI abnormalities exist in a subset of patients with chronic fatigue syndrome. J Neurol Sci 171(1): 3-7.
53. Maes M, Mihaylova I, De Ruyter M (2006) Lower serum zinc in chronic fatigue syndrome (CFS): relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. J Affect Disord 90(2-3): 141-147. doi: 10. 1016/j. jad. 2005. 11. 002.
54. Maes M, Mihaylova I, Leunis JC (2006) Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett 27(5): 615-621.
55. Wilson A, Hickie I, Hadzi-Pavlovic D, Wakefield D, Parker G, Straus SE, Dale J, McCluskey D, Hinds G, Brickman A, Goldenberg D, Demitrack M, Blakely T, Wessely S, Sharpe M, Lloyd A (2001) What is chronic fatigue syndrome? Heterogeneity within an international multicentre study. Aust NZ J Psychiatry 35(4): 520-527.
56. Shepherd C (1992) Chronic fatigue syndrome: a joint paediatric-psychiatric approach. Arch Dis Child 67(11): 1410.
57. Nijhof SL, Maijer K, Bleijenberg G, Uiterwaal CS, Kimpen JL, van de Putte EM (2011) Adolescent chronic fatigue syndrome: prevalence, incidence, and morbidity. Pediatrics 127(5): e1169-e1175. doi: 10. 1542/peds. 2010-1147.
58. Capelli E, Zola R, Lorusso L, Venturini L, Sardi F, Ricevuti G (2010) Chronic fatigue syndrome/myalgic encephalomyelitis: an update. Int J Immunopathol Pharmacol 23(4): 981-989.
59. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles ACP, Speight N, Vallings R, Bateman L, Baumgarten-Austrheim B, Bell DS, Carlo-Stella N, Chia J, Darragh A, Jo D, Lewis D, Light AR, Marshall-Gradisbik S, Mena I, Mikovits JA, Miwa K, Murovska M, Pall ML, Stevens S (2011) Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med 270(4): 327-338. doi: 10. 1111/j. 1365 2796. 2011. 02428. x.
60. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121(12): 953-959.
61. Ogawa M, Nishiura T, Yoshimura M, Horikawa Y, Yoshida H, Okajima Y, Matsumura I, Ishikawa J, Nakao H, Tomiyama Y, Kanayama Y, Kanakura Y, Matsuzawa Y (1998) Decreased nitric oxide-mediated natural killer cell activation in chronic fatigue syndrome. Eur J Clin Invest 28(11): 937-943.
62. Whiteside TL, Friberg D (1998) Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med 105(3A): 27S-34S.
63. Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herberman RB (1998) Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol 88(1): 96-104.
64. Ojo-Amaize EA, Conley EJ, Peter JB (1994) Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis 18(Suppl 1): S157-S159.
65. Pasi A, Bozzini S, Carlo-Stella N, Martinetti M, Bombardieri S, De Silvestri A, Salvaneschi L, Cuccia M (2011) Excess of activating killer cell immunoglobulinlike receptors and lack of HLA-Bw4 ligands: a twoedged weapon in chronic fatigue syndrome. Mol Med Rep 4(3): 535-540. doi: 10. 3892/mmr. 2011. 447.
66. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, Trowsdale J, Wilson M, O'Brien SJ, Carrington M (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31(4): 429-434. doi: 10. 1038/ng934.
67. Jennes W, Verheyden S, Demanet C, Adje-Toure CA, Vuylsteke B, Nkengasong JN, Kestens L (2006) Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 177(10): 6588-6592.
68. Uhrberg M (2005) The KIR gene family: life in the fast lane of evolution. Eur J Immunol 35(1): 10-15. doi: 10. 1002/eji. 200425743.
69. Klimas NG, Salvato FR, Morgan R, Fletcher MA (1990) Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 28(6): 1403-1410.
70. Tirelli U, Marotta G, Improta S, Pinto A (1994) Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 40(6): 601-608.
71. Thoren FB, Romero AI, Hermodsson S, Hellstrand K (2007) The CD16-/CD56bright subset of NK cells is resistant to oxidant-induced cell death. J Immunol 179(2): 781-785.
72. Harlin H, Hanson M, Johansson CC, Sakurai D, Poschke I, Norell H, Malmberg KJ, Kiessling R (2007) The CD16-CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16 + CD56(dim) subset. J Immunol 179(7): 4513-4519.
73. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5(12): 1260-1265. doi: 10. 1038/ni1138.
74. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, Wu L, Butcher EC (2001) Unique subpopulations of CD56 + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 166(11): 6477-6482.
75. Robinson E, Keystone EC, Schall TJ, Gillett N, Fish EN (1995) Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol 101(3): 398-407.
76. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF (2004) CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 173(10): 6418-6426.
77. Wulff S, Pries R, Borngen K, Trenkle T, Wollenberg B (2009) Decreased levels of circulating regulatory NK cells in patients with head and neck cancer throughout all tumor stages. Anticancer Res 29(8): 3053-3057.
78. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, O'Shea MA, Kinter A, Kovacs C, Moretta A, Fauci AS (2005) Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 102(8): 2886-2891. doi: 10. 1073/pnas. 0409872102.
79. Robertson MJ, Schacterle RS, Mackin GA, Wilson SN, Bloomingdale KL, Ritz J, Komaroff AL (2005) Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. Clin Exp Immunol 141(2): 326-332. doi: 10. 1111/j. 1365-2249. 2005. 02833. x.
80. See DM, Cimoch P, Chou S, Chang J, Tilles J (1998) The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome. Integr Physiol Behav Sci 33(3): 280-287.
81. Mawle AC, Nisenbaum R, Dobbins JG, Gary HE Jr, Stewart JA, Reyes M, Steele L, Schmid DS, Reeves WC (1997) Immune responses associated with chronic fatigue syndrome: a case-control study. J Infect Dis 175(1): 136-141.
82. Masuda A, Nozoe SI, Matsuyama T, Tanaka H (1994) Psychobehavioral and immunological characteristics of adult people with chronic fatigue and patients with chronic fatigue syndrome. Psychosom Med 56(6): 512-518.
83. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA (1994) Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis Off Publ Infect Dis Soc Am 18(Suppl 1): S136-S141.
84. Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ (2007) Apoptosis induced by the lymphocyte effector molecule perforin. Curr Opin Immunol 19(3): 339-347. doi: 10. 1016/j. coi. 2007. 04. 007.
85. Saiki T, Kawai T, Morita K, Ohta M, Saito T, Rokutan K, Ban N (2008) Identification of marker genes for differential diagnosis of chronic fatigue syndrome. Mol Med 14(9-10): 599-607. doi: 10. 2119/2007-00059. Saiki.
86. Clark WR (1994) Immunology. The hole truth about perforin. Nature 369(6475): 16-17. doi: 10. 1038/369016a0.
87. Walsh CM, Matloubian M, Liu CC, Ueda R, Kurahara CG, Christensen JL, Huang MT, Young JD, Ahmed R, Clark WR (1994) Immune function in mice lacking the perforin gene. Proc Natl Acad Sci USA 91(23): 10854-10858.
88. Freud AG, Caligiuri MA (2006) Human natural killer cell development. Immunol Rev 214: 56-72. doi: 10. 1111/j. 1600-065X. 2006. 00451. x.
89. Salcedo TW, Azzoni L, Wolf SF, Perussia B (1993) Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. J Immunol 151(5): 2511-2520.
90. Brady J, Hayakawa Y, Smyth MJ, Nutt SL (2004) IL-21 induces the functional maturation of murine NK cells. J Immunol 172(4): 2048-2058.
91. Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG (2009) Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 7: 96. doi: 10. 1186/1479-5876-7-96.
92. Broderick G, Katz BZ, Fernandes H, Fletcher MA, Klimas NG, Smith FA, O'Gorman MR, Vernon SD, Taylor R (2012) Cytokine expression profiles of immune imbalance in post-mononucleosis chronic fatigue. J Transl Med 10(1): 191. doi: 10. 1186/1479-5876-10-191.
93. Bossi G, Griffiths GM (2005) CTL secretory lysosomes: biogenesis and secretion of a harmful organelle. Semin Immunol 17(1): 87-94. doi: 10. 1016/j. smim. 2004. 09. 007.
94. Kam CM, Hudig D, Powers JC (2000) Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors. Biochim Biophys Acta 1477(1-2): 307-323.
95. Tang H, Li C, Wang L, Zhang H, Fan Z (2012) Granzyme H of cytotoxic lymphocytes is required for clearance of the hepatitis B virus through cleavage of the hepatitis B virus X protein. J Immunol 188(2): 824-831. doi: 10. 4049/jimmunol. 1102205.
96. Zhong C, Li C, Wang X, Toyoda T, Gao G, Fan Z (2012) Granzyme K inhibits replication of influenza virus through cleaving the nuclear transport complex importin alpha1/beta dimer of infected host cells. Cell Death Differ 19(5): 882-890. doi: 10. 1038/cdd. 2011. 178.
97. Ewen CL, Kane KP, Bleackley RC (2012) A quarter century of granzymes. Cell Death Differ 19(1): 28-35. doi: 10. 1038/cdd. 2011. 153.
98. Tak PP, Spaeny-Dekking L, Kraan MC, Breedveld FC, Froelich CJ, Hack CE (1999) The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol 116(2): 366-370.
99. Morris G, Maes M (2012) Increased nuclear factor-kappaB and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Hypotheses 79(5): 607-613. doi: 10. 1016/j. mehy. 2012. 07. 034.
100. Maes M, Twisk FN, Ringel K (2012) Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. Psychother Psychosom 81(5): 286-295. doi: 10. 1159/000336803.
101. Al Omar SY, Marshall E, Middleton D, Christmas SE (2011) Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology 133(1): 94-104. doi: 10. 1111/j. 1365-2567. 2011. 03415. x.
102. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7(6): 753-763.
103. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, Phillips JH, Lanier LL, Parham P (1997) Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7(6): 739-751.
104. Pando MJ, Gardiner CM, Gleimer M, McQueen KL, Parham P (2003) The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol 171(12): 6640-6649.
105. Boulet S, Song R, Kamya P, Bruneau J, Shoukry NH, Tsoukas CM, Bernard NF (2010) HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J Immunol 184(4): 2057-2064. doi: 10. 4049/jimmunol. 0902621.
106. Lopez-Larrea C, Blanco-Gelaz MA, Torre-Alonso JC, Bruges Armas J, Suarez-Alvarez B, Pruneda L, Couto AR, Gonzalez S, Lopez-Vazquez A, Martinez-Borra J (2006) Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthr Res Ther 8(4): R101. doi: 10. 1186/ar1988.
107. Tomescu C, Duh FM, Hoh R, Viviani A, Harvill K, Martin MP, Carrington M, Deeks SG, Montaner LJ (2012) Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. Aids 26(15): 1869-1878. doi: 10. 1097/QAD. 0b013e32835861b0.
108. Jiang Y, He L, Chen H, Bice T, Zhang Z, Liu J, Ding H, Han X, Shang H (2011) Alteration of inhibitory and activating NK cell receptor expression on NK cells in HIV-infected Chinese. Cell Immunol 271(2): 219-226. doi: 10. 1016/j. cellimm. 2011. 06. 026.
109. Morvan M, Willem C, Gagne K, Kerdudou N, David G, Sebille V, Follea G, Bignon JD, Retiere C (2009) Phenotypic and functional analyses of KIR3DL1+ and KIR3DS1+ NK cell subsets demonstrate differential regulation by Bw4 molecules and induced KIR3DS1 expression on stimulated NK cells. J Immunol 182(11): 6727-6735. doi: 10. 4049/jimmunol. 0900212.
110. Kupfer DM, Burian D (2008) MicroRNA: the newest player in gene expression regulation. Aviat Space Environ Med 79(5): 550-551.
111. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J (2012) Serum MicroRNA-155 as a potential biomarker to track disease in breast cancer. PLoS ONE 7(10): e47003. doi: 10. 1371/journal. pone. 0047003.
112. Brenu EW, Ashton KJ, van Driel M, Staines DR, Peterson D, Atkinson GM, Marshall-Gradisnik SM (2012) Cytotoxic lymphocyte microRNAs as prospective biomarkers for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Affect Disord 141(2-3): 261-269. doi: 10. 1016/j. jad. 2012. 03. 037.
113. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF (2007) miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci USA 104(17): 7080-7085. doi: 10. 1073/pnas. 0702409104.
114. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14): 6029-6033. doi: 10. 1158/0008-5472. CAN-05-0137.
115. Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L, Bandres E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, Perez-Roger I, Garcia-Foncillas J, Torres A, Heiniger A, Calasanz MJ, Fortes P, Roman-Gomez J, Prosper F (2008) Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res MCR 6(12): 1830-1840. doi: 10. 1158/1541-7786. MCR-08-0167.
116. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF (2010) MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci USA 107(30): 13450-13455. doi: 10. 1073/pnas. 1002120107.
117. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103(33): 12481-12486. doi: 10. 1073/pnas. 0605298103.
118. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 3(7): e2557. doi: 10. 1371/journal. pone. 0002557.
119. Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM, Lindsay MA (2008) Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol 180(8): 5689-5698.
120. Sonkoly E, Pivarcsi A (2011) MicroRNAs in inflammation and response to injuries induced by environmental pollution. Mutat Res 717(1-2): 46-53. doi: 10. 1016/j. mrfmmm. 2011. 02. 002.
121. Wu GQ, Zhao YM, Huang H, Lai XY (2011) Effects of blocking inhibitory KIR receptors on cytotoxic activity of human NK cells in vitro. Zhejiang Da Xue Xue Bao Yi Xue Ban 40(5): 475-481.
122. Wiborg JF, van der Werf S, Prins JB, Bleijenberg G (2010) Being homebound with chronic fatigue syndrome: a multidimensional comparison with outpatients. Psychiatry Res 177(1-2): 246-249. doi: 10. 1016/j. psychres. 2010. 02. 010.
123. Siegmund D, Wicovsky A, Schmitz I, Schulze-Osthoff K, Kreuz S, Leverkus M, Dittrich-Breiholz O, Kracht M, Wajant H (2005) Death receptor-induced signaling pathways are differentially regulated by gamma interferon upstream of caspase 8 processing. Mol Cell Biol 25(15): 6363-6379. doi: 10. 1128/MCB. 25. 15. 6363-6379. 2005.
124. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O'Brien SJ, Rosenberg WM, Thomas DL, Carrington M (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305(5685): 872-874. doi: 10. 1126/science. 1097670.
125. Stern M, Ruggeri L, Capanni M, Mancusi A, Velardi A (2008) Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood 112(3): 708-710. doi: 10. 1182/blood-2008-02-137521.
126. Franceschelli S, Rosati A, Lerose R, De Nicola S, Turco MC, Pascale M (2008) Bag3 gene expression is regulated by heat shock factor 1. J Cell Physiol 215(3): 575-577. doi: 10. 1002/jcp. 21397.
127. Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, Yawata M, Easterbrook P, McVicar DW, Maenaka K, Parham P, Carrington M, Dong T, Rowland-Jones S (2007) Cutting Edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 178(1): 33-37.
128. Scrivo R, Morrone S, Spadaro A, Santoni A, Valesini G (2011) Evaluation of degranulation and cytokine production in natural killer cells from spondyloarthritis patients at single-cell level. Cytom Part B Clin Cytom 80(1): 22-27. doi: 10. 1002/cyto. b. 20549.
129. Castoldi L, Golim MA, Filho OG, Romagnoli GG, Ibanez OC, Kaneno R (2007) Enhanced natural killer activity and production of pro-inflammatory cytokines in mice selected for high acute inflammatory response (AIRmax). Immunology 120(3): 372-379. doi: 10. 1111/j. 1365-2567. 2006. 02513. x.
130. Lunemann A, Lunemann JD, Munz C (2009) Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med 15(9-10): 352-358. doi: 10. 2119/molmed. 2009. 00035.